Purpose of Study:
A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban(Xarelto®) for high risk people with mild COVID-19.
September 1, 2020 - Ongoing
Type of Study:
Allergy & Asthma Medical Group and Research Center A P.C
Bill & Melinda Gates Medical Research Institute